Simple Summary There is a need to improve the conventional treatment options for lung
cancer. Immunotherapy is based on the premise that therapeutic drugs destroy tumor cells …

Tumor immunotherapy is praised as “green therapy,” which can attack tumor by mobilizing
immune system. By removing the inhibition of immune cells, checkpoint inhibitors help T …

From radiation therapy and surgery to chemotherapy and targeted therapy, the treatment of
non-small cell lung cancer (NSCLC) has remarkably evolved over the past few decades. In …

For advanced metastatic non-small-lung cancer, the landscape of actionable driver
alterations is rapidly growing, with nine targetable oncogenes and seven approvals within …

Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of
lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) …

Abstract Treatment of lung cancer remains a challenge, and lung cancer is still the leading
cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but …

Immune checkpoint inhibitors have significantly improved overall survival with an acceptable
safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients …

Opinion statement Targeted therapies and more recently immune checkpoint inhibitors (ICI)
have transformed the treatment landscape of advanced NSCLC. Clinical trials investigating …

Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer
(NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet …

Immunotherapy has prompted a paradigm shift in advanced non-small cell lung cancer
(NSCLC) treatment, by demonstrating superior efficacy to chemotherapy alone both in …